| Gene symbol | CD5 | Synonyms | LEU1, T1 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | CD5 molecule | ||||
| GTO ID | GTC2600 |
| Trial ID | NCT04767308 |
| Disease | Chronic Lymphocytic Leukemia | Refractory Hematologic Cancer | Diffuse Large B-Cell Lymphoma | Follicular Lymphoma | Mantle Cell Lymphoma | Peripheral T-Cell Lymphoma |
| Altered gene | CD5 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CT125A |
| Phase | Early_Phase1 |
| Recruitment status | Not Recruiting |
| Title | Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies |
| Year | 2021 |
| Country | China |
| Company sponsor | Huazhong University of Science and Technology |
| Other ID(s) | CT125ACI001 |
| Cohort 1 | |||||||||||
|
|||||||||||